Resamirigene bilparvovec (codename: AT132) is an experimental gene therapy medication studied as a treatment for X-linked myotubular myopathy (XLMTM), a severe and usually fatal genetic disorder affecting mainly male infants and caused by a mutation in the MTM1 gene.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.